Replies to post #103003 on Biotech Values

[iwfal]

Ok, that's clear. Thanks.

[jbog]

Ok,

I can use three pieces of published data and come up with the same answer, but it's no where close to your answer.

Data #1... Sandoz said in the court petition it expected M-enox sales to be $40 million over the next 6 weeks.

$40/6= $6.6 mil/wk X 13 weeks= $86.6 mil/qtr

$86.6 - 30% (cog)= $60.6 mil gross profit per qtr

$60.6 X 45% = $27.3 mil/qtr Momenta Share

$27.3 X .5 = $13.75 mil/ Sandoz Reimbursement, $13.75 mil MNTA Revenue

====================================================================

Data #2 We believe Momenta will have to reimburse Sandoz 45% of the $60mil in Development costs over two quarters.

$60mil X 45% = $27 mil total due

From the previous data, Momenta would reimburse Sandoz $13.75 mil per quarter up to the $27 mil limit.

Answer= Sales are (or were) estimated at $6.6 million per week.


Sounds right??????